Medicament diffusing device

Abstract

In order to provide a medicament diffusing device with a long duration of medicament diffusing performance, when the housing container (6) is switched from an upright posture to an inverted posture in which the top and bottom are reversed relative to the upright posture, the inner container (10) descends under the action of gravity, the outer opening portion (20a) of the outer container (20) which is open in the peripheral surface thereof overlaps the inner opening portion (10a) of the inner container (10) which is open in the peripheral surface thereof in one of the upright posture and the inverted posture, and the inner opening portion (10a) is offset relative to the outer opening portion (20a) in the up-down direction and the outer opening portion (20a) is blocked by the periphery of the inner opening portion (10a) in the other of the upright posture and the inverted posture.

Description

Technical Field

[0001] This invention relates to a pesticide volatilization device for volatilizing volatile pesticides such as insect repellents. Background Technology

[0002] Conventional pharmaceutical vaporization devices include a device for holding a volatile pharmaceutical agent as a vaporizable substance and a container for housing the vaporizable substance in a ventilable container. Multiple openings are provided on the periphery of the container. The pharmaceutical agent vaporized from the vaporizable substance is released to the outside through these openings (e.g., Patent Document 1).

[0003] While conventional technologies offer excellent diffusion due to the continuous release of volatile agents, further improvements are needed to address the sustainability of agent dispersion. Additionally, even with volatile agents that are odorless and have relatively high safety, there are still challenges in dispersing them in spaces with volumes ranging from 2.0 to 33.3 m³, such as indoor spaces (toilets, bathrooms, bedrooms, living rooms, etc.), vehicles, and tents. 3 Consumers who are always wary of drug evaporation in confined spaces (including those with natural ventilation or 24-hour ventilation) are therefore looking for drug evaporation devices that can cause the drug to evaporate only during use or for a limited time.

[0004] At this point, a structure that allows for easy switching between a volatile state (when in use) and a non-volatile state (when not in use) is preferred. It is desirable to further simplify the process, especially in cases where the volatile and non-volatile states are switched at high frequencies (e.g., at intervals of less than 12 hours), but a drug volatile device that can perform such switching with relatively simple operation has not yet been found.

[0005] Existing technical documents

[0006] Patent documents

[0007] Patent Document 1: Japanese Patent Application Publication No. 2023-101180 Summary of the Invention

[0008] The problem that the invention aims to solve

[0009] The purpose of this invention is to provide a drug volatilization device that can easily switch between a volatilization state (when in use) and a non-volatilization state (when not in use) through relatively simple operation, without causing a continuous reduction in the drug volatilization performance.

[0010] Solution for solving the problem

[0011] A pharmaceutical vaporization device according to a first aspect of the present invention comprises a receiving container for maintaining a volatile pharmaceutical agent as a vaporizable pharmaceutical agent and a receiving container having an outer container disposed outside an inner container for receiving the vaporizable pharmaceutical agent. The pharmaceutical vaporization device is characterized in that, when the receiving container is switched to an upright position and an inverted position relative to the upright position with the top and bottom reversed, the inner container descends under its own weight. In one of the upright and inverted positions, the outer opening of the circumferential opening of the outer container overlaps with the inner opening of the circumferential opening of the inner container. In the other of the upright and inverted positions, the inner opening is offset vertically relative to the outer opening, and the outer opening is blocked by the periphery of the inner opening.

[0012] The second aspect of the present invention provides a drug dispersing device comprising a drug dispersible body that retains a volatile drug as a dispersible drug dispersible body and a receiving container having an outer container disposed outside an inner container that receives the drug dispersible body. The drug dispersing device is characterized in that the inner container, which is made of a sheet-formed synthetic resin, is vertically movable relative to the outer member, which is made of an injection-molded synthetic resin. By moving the inner container vertically, it is possible to switch between a dispersing state in which the outer opening of the outer container overlaps with the inner opening of the inner container, and a non-dispersing state in which the inner opening is offset vertically relative to the outer opening and the outer opening is blocked by the periphery of the inner opening.

[0013] Invention Effects

[0014] According to the first and second aspects of the present invention, the user can easily switch between a volatile state with the outer opening open and a non-volatile state with the outer opening closed by selectively setting the storage container to an upright position and an inverted position. Thus, when not in use, switching to the non-volatile state suppresses the harmful volatile dispersion of the drug, thereby maintaining the continuity of the drug's volatile properties. Attached Figure Description

[0015] Figure 1 This is a perspective view showing the pharmaceutical vaporization device according to the first embodiment of the present invention.

[0016] Figure 2 This is an exploded perspective view showing the pharmaceutical vaporization device according to the first embodiment of the present invention.

[0017] Figure 3 This is a front view showing the inner container of the pharmaceutical vaporization device according to the first embodiment of the present invention.

[0018] Figure 4This is a side sectional view showing the inner container of the pharmaceutical vaporization device according to the first embodiment of the present invention.

[0019] Figure 5 This is a perspective view showing the state of the inner container of the pharmaceutical vaporization device according to the first embodiment of the present invention.

[0020] Figure 6 This is a cross-sectional view of the upper part of the outer container of the drug dispersing device according to the first embodiment of the present invention.

[0021] Figure 7 This is a cross-sectional view of the lower part of the outer container of the drug dispersing device according to the first embodiment of the present invention.

[0022] Figure 8 This is a cross-sectional view of the upper part showing the stacked state of the surface components of the drug dispersing device according to the first embodiment of the present invention.

[0023] Figure 9 This is a lower cross-sectional view showing the stacked state of the surface components of the drug dispersing device according to the first embodiment of the present invention.

[0024] Figure 10 This is a cross-sectional view of the upper part showing the stacked state of the back-side components of the drug dispersing device according to the first embodiment of the present invention.

[0025] Figure 11 This is a lower cross-sectional view showing the stacked back-side components of the pharmaceutical vaporization device according to the first embodiment of the present invention.

[0026] Figure 12 This is a side sectional view showing the storage container of the drug dispersing device according to the first embodiment of the present invention in an upright position.

[0027] Figure 13 This is a side sectional view showing the storage container of the drug dispersing device according to the first embodiment of the present invention in an inverted position.

[0028] Figure 14 This is a perspective view showing the drug dispersing device according to the second embodiment of the present invention.

[0029] Figure 15 This is an exploded perspective view showing the drug dispersing device according to the second embodiment of the present invention.

[0030] Figure 16 This is a perspective view showing the state of the inner container of the pharmaceutical vaporization device according to the second embodiment of the present invention.

[0031] Figure 17This is a side sectional view showing the storage container of the drug dispersing device according to the second embodiment of the present invention in an upright position.

[0032] Figure 18 yes Figure 17 Enlarged view of part D.

[0033] Figure 19 This is a side sectional view showing the storage container of the drug dispersing device according to the second embodiment of the present invention in an inverted position.

[0034] Figure 20 yes Figure 19 Enlarged view of part E. Detailed Implementation

[0035] <First Implementation>

[0036] The embodiments of the present invention will be described below with reference to the accompanying drawings. Figure 1 , Figure 2 A perspective view and an exploded perspective view of the pesticide dispersing device 1 according to the first embodiment are shown. The pesticide dispersing device 1 releases volatile pesticides such as insecticides or insect repellents to repel or avoid flying pests such as mosquitoes.

[0037] The drug dispersing device 1 includes a drug dispersant 5 and a receiving container 6. The receiving container 6 has an inner container 10 for receiving the drug dispersant 5 and an outer container 20 disposed on its outer side, with the outer container 20 covering the inner container 10. The drug dispersing device 1 is erected, for example on a table, and releases the volatile drug dispersing from the drug dispersant 5 through an outer opening 20a that opens on the circumference of the outer container 20.

[0038] As the pharmaceutical volatile 5, for example, a pharmaceutical volatile that maintains a volatile pharmaceutical agent in a volatile structure through impregnation, internal addition, etc. can be used. Examples of raw materials for the pharmaceutical volatile 5 include paper, pulp, natural fibers, synthetic fibers, resin bodies, resin sheets, inorganic / organic porous bodies, gels, etc.

[0039] The method of impregnating resin sheets with chemicals is simple, but from the perspective of easy control of the slow release of volatile chemicals during use, stable chemical evaporation, and suppression of chemical loss caused by rain or other moisture when used outdoors, it is preferable to use a resin body with added volatile chemicals, but this is not particularly limited.

[0040] Examples of resins used as resin bodies and resin sheets include polyethylene, polypropylene, polyvinyl alcohol, polyvinyl acetate, polybutadiene, polyisoprene, ethylene-vinyl acetate copolymer, ethylene-methyl methacrylate copolymer, and styrene-butadiene copolymer.

[0041] The morphology of the drug volatile 5 is not particularly limited to flakes, granules, three-dimensional forms, etc., but from the viewpoint of improving the volatile drug's volatilization efficiency, it can be, for example, a honeycomb structure, an open-pore structure, a planar or three-dimensional mesh structure, etc.

[0042] Volatile pesticides can be used alone or in combination with insecticides, repellents, fungicides, antibacterial agents, fragrances, deodorizers, synergists, etc., but are not particularly limited in their use. For example, when used to repel or control flying pests such as mosquitoes, midges, and moth flies, pyrethroid compounds are preferred as volatile pesticides. In particular, room-temperature volatile pyrethroid compounds such as methoxyfenozide, propofol, dextromethorphan, and tetrafluorobenzyl are suitable due to their high volatility and control efficacy against flying pests. It should be noted that volatile pesticides can be used in combination with known non-volatile pesticides.

[0043] The inner container 10 is a resin molded product formed by injection molding and contains the drug volatiles 5. The inner container 10 covers the front surface and back surface of the drug volatiles 5 respectively by interlocking front and back components 11 and back component 12.

[0044] Figure 3 , Figure 4 The front view and side sectional view of the inner container 10 are shown. A pair of left and right engaging claws 15a protruding rearward are provided at the upper end of the surface member 11 of the inner container 10. Similarly, a pair of left and right engaging claws 15b protruding rearward are provided at the lower end of the surface member 11 of the inner container 10. Furthermore, a locking portion 16 that engages with the engaging claws 15a and 15b is provided on the back member 12 of the inner container 10. The drug vapor 5 is contained within the inner container 10 through the engagement of the engaging claws 15a and 15b with the locking portion 16.

[0045] The left-right spacing of the engaging claws 15a at the upper end of the front member 11 is different from the left-right spacing of the engaging claws 15b at the lower end. This prevents the front member 11 and the back member 12 from being installed in opposite vertical directions. It should be noted that a engaging portion 16 may also be provided on the front member 11, and engaging claws 15a and 15b may be provided on the back member 12.

[0046] Alternatively, the surface member 11 and the back member 12 can be integrally formed using a hinge at one end in the vertical direction, and engaging claws and engaged portions can be provided at the other end. Furthermore, the surface member 11 and the back member 12 can cover both sides of the drug volatile 5 and be bonded together using ultrasound or the like.

[0047] Multiple rectangular inner openings 10a are formed on the circumference of the inner container 10 by a grid-like lattice 10b. Volatile pharmaceuticals emitted from the pharmaceutical volatiles 5 flow out from the inner openings 10a and are directed to the outer openings 20a of the outer container 20.

[0048] First protrusions 14 are provided on the outer surfaces of both sides of the inner container 10. A widening portion 13, which is wider in the left and right direction than the upper portion, is provided at the lower end of the inner container 10. The width of the widening portion 13 in the left and right direction is greater than the width of the first protrusions 14 in the left and right direction of the inner container 10.

[0049] like Figure 5 As shown, the inner container 10 is inserted into the insertion hole 20c provided on the lower end face of the outer container 20 from the opposite side of the widened portion 13. Therefore, the inner container 10 can be attached to and detached from the outer container 20, allowing for easy replacement of the entire inner container 10 or the drug vapor 5 within it. However, it is also possible to configure the inner container 10 so that it cannot be removed after assembly.

[0050] A pair of second protrusions 24 are provided on the inner surface of the outer container 20 (see reference). Figure 2 The left-right spacing of the inner surface of the second protrusion 24 is smaller than the left-right spacing of the outer surface of the first protrusion 14. Therefore, the first protrusion 14 inserted into the inner container 10 of the outer container 20 slides and elastically deforms with respect to the second protrusion 24, thus passing over the second protrusion 24.

[0051] Thus, the first protrusion 14 is positioned above the second protrusion 24, and the inner container 10 is assembled. Furthermore, the first protrusion 14 abuts against the second protrusion 24, thereby restricting the vertical movement (descent) of the inner container 10.

[0052] Furthermore, when the inner container 10 is inserted into the through hole 20c from the widened portion 13 in the opposite direction, the widened portion 13 abuts against the second protrusion 24, thus hindering the movement of the inner container 10. This prevents misassembly of the inner container 10.

[0053] exist Figure 1 , Figure 2 In this design, the outer container 20 is a resin molded product formed by injection molding, and the inner container 10 is inserted through a through hole 20c provided on one end face (here, the lower surface) in the vertical direction. Thus, the inner container 10 can be detachably mounted to the outer container 20. The outer container 20 has an upper surface opening 20d on its upper surface, and a flange 23 provided around the upper surface opening 20d prevents the inner container 10 from detaching.

[0054] In addition, such as Figure 1 As shown, a portion of the flange 23 has a protrusion 23a that protrudes inward toward the inner surface. As a result, the outer container 20 is configured to prevent the inner container 10 from being accidentally inserted through the upper surface opening 20d.

[0055] In addition, when removing the inner container 10 from the outer container 20, the inner container 10 can be pushed out through the opening 20d on the upper surface of the outer container 20.

[0056] The outer container 20 is formed, for example, of white resin, and the inner container 10 is formed, for example, of colorless, transparent, or gray resin. The outer color of the outer container 20 and the inner container 10 is not limited and may be the same color, but in the case of different color schemes, the difference between the volatile and non-volatile states, which will be described later, is easily discernible.

[0057] The outer container 20 covers the front and back surfaces of the inner container 10 by means of interlocking front and back members 21 and 22, respectively. Multiple rectangular outer openings 20a are formed on the circumference of the outer container 20 by lattice-like strips 20b. The outer openings 20a are formed to be approximately the same size as the inner openings 10a.

[0058] Figure 6 , Figure 7 The images show cross-sectional views of the upper and lower ends of the outer container 20 as viewed from below. A pair of rearwardly protruding left and right engaging claws 25a are provided on the upper end of the side surface member 21 of the outer container 20, and a pair of rearwardly protruding left and right engaging claws 25b are provided on the lower end of the side surface member 21. Furthermore, on the inner surface of the side surface member 21, a pair of left and right ribs 26a are provided inside the engaging claws 25a, and a pair of left and right ribs 26b are provided inside the engaging claws 25b.

[0059] On the upper outer surface of the surface member 21, steps 28a and 29a are provided at the same positions as the engaging claw 25a and rib 26a in the left-right and up-down directions, respectively. On the lower outer surface of the surface member 21, steps 28b and 29b are provided at the same positions as the engaging claw 25b and rib 26b in the left-right and up-down directions, respectively.

[0060] A pair of engaging portions 30a are provided on the upper side of the back member 22 to engage with engaging claws 25a, and a pair of engaging portions 30b are provided on the lower side to engage with engaging claws 25b. Additionally, a pair of opposing walls 31a are provided on the upper side of the back member 22, opposite to the engaging portions 30a, and a pair of opposing walls 31b are provided on the lower side, opposite to the engaging portions 30b. Step portions 33a and 33b are provided on the outer surface of the back member 22 at the same positions as the opposing walls 31a and 31b in both the left-right and up-down directions.

[0061] The engaging claw 25a enters between the engaged portion 30a and the opposing wall 31a and engages with the engaged portion 30a. At this time, the opposing wall 31a enters between the engaging claw 25a and the rib 26a. The engaging claw 25b enters between the engaged portion 30b and the opposing wall 31b and engages with the engaged portion 30a. At this time, the opposing wall 31b enters between the engaging claw 25b and the rib 26b.

[0062] The width of the opposing wall 31b in the left-right direction is greater than that of the opposing wall 31a in the left-right direction. Therefore, when the top and bottom are reversed so that the back member 22 covers the front member 21, the opposing wall 31b abuts against the rib 26a and hinders the engagement of the engaging claw 25a. As a result, misassembly of the front member 21 and the back member 22 can be prevented.

[0063] The opposing wall 31a has a protrusion 32a facing the engaging claw 25a and positioned forward of the engaging portion 30a in the insertion direction. Therefore, the engaging claw 25a, which travels between the engaging portion 30a and the opposing wall 31a, is guided along the protrusion 32a and engaged with the engaging portion 30a by elastic deformation.

[0064] Similarly, the opposing wall 31b has a protrusion 32b facing the engaging claw 25b and positioned forward of the engaging portion 30b in the insertion direction. Therefore, the engaging claw 25b, traveling between the engaging portion 30b and the opposing wall 31b, is guided along the protrusion 32b and engaged with the engaging portion 30b by elastic deformation. Thus, the inner container 10 is housed within the outer container 20.

[0065] The gap between the engaging claws 25a, 25b that engage with the engaging portions 30a, 30b and the opposing walls 31a, 31b is narrowed by the protrusions 32a, 32b. Therefore, it is possible to prevent the engagement between the front member 21 and the back member 22 from being released due to impacts such as the falling of the drug dispersing device 1.

[0066] Figure 8 , Figure 9This is a top and bottom cross-sectional view showing the stacked state of the outer container 20 during assembly. Engaging claws 25a' and ribs 26a' of the stacked outer container 21' are arranged on the stepped portions 28a and 29a of the outer container 21. Engaging claws 25b' and ribs 26b' of the stacked outer container 21' are arranged on the stepped portions 28b and 29b of the outer container 21. This allows for stable stacking of the outer container 21, improving the ease of assembly of the outer container 20.

[0067] Figure 10 , Figure 11 This is a top and bottom cross-sectional view showing the stacked back-side members 22 during the assembly of the outer container 20. Opposing walls 31a' of the stacked back-side members 22' are arranged on the stepped portion 33a of the back-side members 22. Opposing walls 31b' of the stacked back-side members 22' are arranged on the stepped portion 33b of the back-side members 22. This allows for stable stacking of the back-side members 22, improving the ease of assembly of the outer container 20.

[0068] It should be noted that engaging portions 30a and 30b and opposing walls 31a and 31b may also be provided on the front side member 21, and engaging claws 25a and 25b and ribs 26a and 26b may be provided on the back side member 12.

[0069] Figure 12 The side sectional view of the drug dispersing device 1 is shown with the storage container 6 in an upright position. Figure 13 This is a side sectional view of the drug dispersing device 1 when the receiving container 6 is in an inverted position with its top and bottom reversed relative to its upright position. The inner container 10 can move up and down within the outer container 20 under its own weight. Therefore, in the upright position, the inner container 10, which descends under its own weight, passes through the first protrusion 14 (see reference 14). Figure 3 ) and the second protrusion 24 (refer to Figure 2 Its vertical movement is restricted by the contact with the object.

[0070] At this time, the inner opening 10a inside the storage container 6 overlaps with the outer opening 20a, and the outer opening 20a is open. Thus, the volatile agent emitted from the drug vaporizer 5 is released through the inner opening 10a and the outer opening 20a into the space where the drug vaporizer 1 is installed. That is, the drug vaporizer 1 is in a vaporization state that disperses the volatile agent to the outside.

[0071] Furthermore, when the storage container 6 is moved from an upright position to an inverted position as shown by arrow A, the inner container 10, which descends under its own weight, is restricted from moving up and down by the contact between its end face and the flange 23 in the vertical direction. At this time, the inner opening 10a is offset from the outer opening 20a in the vertical direction, and the outer opening 20a is blocked by the ribs 10b surrounding the inner opening 10a.

[0072] Therefore, the volatile agent evaporating from the agent evaporator 5 is blocked by the lint 10b around the inner opening 10a and the lint 20b around the outer opening 20a, and its release to the outside is suppressed. That is, the agent evaporation device 1 is in a non-volatile state where the evaporation of the volatile agent has stopped. Thus, by setting it to an upright position when needed and an inverted position when not needed, the amount of agent used can be adjusted, and the continuity of the agent evaporation performance can be maintained.

[0073] Furthermore, when the outer container 20 and the inner container 10 are given different exterior colors, the lint 10b of the inner container 10, which has a different exterior color from the outer container 20, can be visually confirmed from the outer opening 20a, and is therefore identified as being in a non-volatile state. Thus, it is useful to be able to easily distinguish between a volatile state and a non-volatile state.

[0074] Furthermore, the inner opening 10a and the outer opening 20a are formed into a rectangle by lattice-like strips 10b and 20b, but they can also be other shapes as long as the outer opening 20a can be sealed by the surrounding area of ​​the inner opening 10a. In addition, the container 6 is set to a dissipated state when it is upright and a non-dissipated state when it is upside down, but it is also possible to set it to a non-dissipated state when it is upright and a dissipated state when it is upside down.

[0075] According to this embodiment, by selectively setting the drug dispersing device 1 to either an upright or an inverted position, the user can easily switch between a dispersing state with the outer opening 20a open and a non-dispersing state with the outer opening 20a closed, i.e., to connect / disconnect for use and non-use. Therefore, when not in use, switching to the non-dispersing state suppresses the harmful dispersal of volatile drugs, thus maintaining the continuity of drug dispersing performance.

[0076] Furthermore, the first protrusion 14 protruding from the outer surface of the inner container 10 abuts against the second protrusion 24 protruding from the inner surface of the outer container 20, thereby restricting the vertical movement of the inner container 10. Therefore, the inner opening 10a can be easily positioned relative to the outer opening 20a and configured in either a volatile or non-volatile state.

[0077] Furthermore, the inner container 10 is inserted into the insertion hole 20c of the outer container 20 and is designed for easy insertion and removal. When inserted into the insertion hole 20c, the first protrusion 14 slides past the second protrusion 24. This allows for the replacement of the drug vapor 5. Additionally, the first protrusion 14, which passes over the second protrusion 24, abuts against the second protrusion 24, thus easily restricting the vertical movement of the inner container 10.

[0078] Furthermore, a widened portion 13 is provided at one end of the inner container 10 in the vertical direction. Therefore, when the widened portion 13 is inserted into the insertion hole 20c, it abuts against the second protrusion 24 and obstructs the movement of the inner container 10. This prevents misassembly of the inner container 10.

[0079] Additionally, the inner container can be designed to be detachable from the outer container, allowing for the replacement of the drug vapor 5. It should be noted that, for example, the insertion hole 20c can be blocked, making the inner container 10 non-detachable from the outer container 20.

[0080] Furthermore, the opposing walls 31a and 31b, which are opposite to the engaging portions 30a and 30b, have protrusions 32a and 32b facing the engaging claws 25a and 25b and positioned further forward in the insertion direction than the engaging portions 30a and 30b. This prevents the engagement between the front member 21 and the back member 22 from being released due to impacts such as the falling of the drug dispersing device 1.

[0081] In addition, the inner container 10 and the outer container 20 have different exterior colors, so it is easy to distinguish between the volatile and non-volatile states.

[0082] <Second Implementation>

[0083] Next, the second embodiment of the present invention will be described. Figure 14 This is a perspective view of the drug volatilization device 1 according to the second embodiment. Figure 15 This is an exploded perspective view of the drug volatilization device 1. Figure 16 This is a perspective view showing the state of the inner container 10 of the assembled drug vaporization device 1. For ease of explanation, the view is similar to that described above. Figures 1-13 The same reference numerals are used for the same parts as in the first embodiment. In the second embodiment, the construction of the inner container 10 and a portion of the internal construction of the outer container 20 differ from the first embodiment. The other parts are the same as in the first embodiment and achieve the same effects.

[0084] The inner container 10 is a sheet-formed synthetic resin product formed by vacuum pressure molding or the like, and has a folded front side member 11 and a back side member 12. By making the inner container 10 a sheet-formed product, the amount of resin used can be reduced compared to injection-molded products, making it an environmentally friendly drug dispersing device 1. Furthermore, the overall thickness and weight of the drug dispersing device 1 can be reduced, thus saving storage space and improving delivery efficiency are expected. It should be noted that, in this embodiment... Figure 2 As shown, the inner container 10 is configured with a folded front member 11 and a back member 12, but each member can also be an independent piece.

[0085] The front member 11 and the back member 12 are provided with flanges 18 around the receiving portion 17 that receives the drug vapor 5. Protruding holes 15 are recessed at the four corners of the flange 18 of the front member 11. Protrusions 16 are protruding at the four corners of the flange 18 of the back member 12. The protrusions 16 fit into the protruding holes 15, thus closing the inner container 10. The front member 11 and the back member 12 respectively cover the front and back surfaces of the drug vapor 5.

[0086] Multiple rectangular inner openings 10a are formed on the bottom surface of the receiving portion 17 of the inner container 10 through a grid-like lattice 10b. Volatile pharmaceutical agents emitted from the pharmaceutical volatiles 5 flow out from the inner openings 10a and are guided to the outer openings 20a of the outer container 20. In addition, first protrusions 14 are provided on the outer surfaces of both sides of the receiving portion 17 of the inner container 10 (see reference). Figure 16 ).

[0087] like Figure 16 As shown, the inner container 10 is inserted into the outer container 20 through the insertion hole 20c provided on the lower end face of the outer container 20. Therefore, the inner container 10 can be attached to and detached from the outer container 20, allowing for easy replacement of the entire inner container 10 or the drug vapor 5 within it. However, it is also possible to configure the inner container 10 so that it cannot be removed after assembly.

[0088] A pair of second protrusions 24 are provided on the inner surface of the outer container 20 (see reference). Figure 15 The left-right spacing of the inner surface of the second protrusion 24 is smaller than the left-right spacing of the outer surface of the first protrusion 14. Therefore, the first protrusion 14 inserted into the inner container 10 of the outer container 20 slides and elastically deforms with respect to the second protrusion 24, thus passing over the second protrusion 24.

[0089] Thus, the first protrusion 14 is positioned above the second protrusion 24, and the inner container 10 is assembled. Furthermore, the first protrusion 14 abuts against the second protrusion 24, thereby restricting the vertical movement (descent) of the inner container 10.

[0090] exist Figure 14 , Figure 15 In this design, the outer container 20 is an injection-molded synthetic resin product, and the inner container 10 is inserted through a through-hole 20c provided on one end face (here, the lower surface) in the vertical direction. Thus, the inner container 10 can be detachably mounted to the outer container 20. An upper surface opening 20d surrounded by a flange 23 is provided on the upper surface of the outer container 20. A limiting member 35 protrudes from the upper inner surface of the outer container 20. The inner container 10 is prevented from detaching by the contact between the peripheral wall of the receiving portion 17 of the inner container 10 and the limiting member 35.

[0091] In addition, such as Figure 14 As shown, a protrusion 23a protruding inward toward the inner surface is provided on a portion of the flange 23. As a result, the outer container 20 is configured to prevent the inner container 10 from being accidentally inserted through the upper surface opening 20d.

[0092] Regarding the inner container 10, it can be inserted into the insertion hole 20c without limiting its vertical orientation, provided that the specified function is met. For example, if the orientation of the inner container 10 during insertion is set to only the vertical direction, then... Figure 16 As shown, a raised portion 19 is provided at one end of the inner container 10. When the inner container 10 is inserted into the outer container 20 from the side of the raised portion 19, the raised portion 19 and the limiting member 35 (see reference) Figure 15 The inner container 10 is obstructed from being fully inserted. Therefore, the orientation of the inner container 10 during insertion is determined to be one direction.

[0093] Figure 17 The image shows a side sectional view of the drug dispersing device 1 with the storage container 6 in an upright position. Figure 18 Show Figure 17 Enlarged view of part D. Figure 19 The image shows a side sectional view of the drug dispersing device 1 when the storage container 6 is positioned in an inverted position with its top and bottom reversed relative to its upright position. Figure 20 Show Figure 12 Enlarged view of part E.

[0094] The inner container 10 descends within the outer container 20 by being pressed down via the insertion hole 20c or the upper surface opening 20d. Therefore, in the upright position, the inner container 10, pressed down via the upper surface opening 20d, descends to the first protrusion 14 (see reference). Figure 16 ) and the second protrusion 24 (refer to Figure 15The end of the journey.

[0095] At this time, within the storage container 6, the inner opening 10a overlaps with the outer opening 20a, and the outer opening 20a is open. Thus, the volatile agent emitted from the drug vaporizer 5 is released through the inner opening 10a and the outer opening 20a into the space where the drug vaporizer 1 is located. That is, the drug vaporizer 1 is in a vaporization state that disperses the volatile agent to the outside.

[0096] Furthermore, when the storage container 6 is moved from an upright position to an inverted position as shown by arrow A, the inner container 10, which is pressed down through the insertion hole 20c, descends to the end of its stroke where the peripheral wall of the storage section 17 abuts against the limiting member 35. At this time, the inner opening 10a is offset vertically relative to the outer opening 20a, and the outer opening 20a is blocked by the ribs 10b surrounding the inner opening 10a.

[0097] Therefore, the volatile agent evaporating from the agent evaporator 5 is blocked by the lint 10b around the inner opening 10a and the lint 20b around the outer opening 20a, and its release to the outside is suppressed. That is, the agent evaporation device 1 is in a non-volatile state where the evaporation of the volatile agent has stopped. Thus, by setting it to an upright position when needed and an inverted position when not needed, the amount of agent used can be adjusted, and the continuity of the agent evaporation performance can be maintained.

[0098] It should be noted that the inner container 10 can also be configured to move up and down within the outer container 20 under its own weight. Furthermore, while the inner opening 10a and the outer opening 20a are formed into rectangles by lattice-like strips 10b and 20b, they can also be shapes other than rectangles, as long as the outer opening 20a can be sealed off by the surrounding area of ​​the inner opening 10a. Additionally, the container 6 is configured to be in a dispersed state when upright and in a non-dispersed state when inverted, but it is also possible to configure it to be in a non-dispersed state when upright and in a dispersed state when inverted.

[0099] According to this embodiment, the user can switch between a volatile state with the outer opening 20a open and a non-volatile state with the outer opening 20a closed by moving the inner container 10 up and down; that is, to connect / disconnect when in use and when not in use. Thus, when not in use, switching to the non-volatile state suppresses the harmful evaporation of volatile agents, thereby maintaining the continuity of agent evaporation performance. Furthermore, by making the inner container 10 a sheet-shaped product, the amount of resin used can be reduced compared to injection-molded products, making it an environmentally friendly agent evaporation device 1. In addition, the overall thickness and weight of the agent evaporation device 1 can be reduced, thus saving storage space and improving delivery efficiency.

[0100] Furthermore, the inner container is in a volatile state when it is positioned either upright or inverted and descends to the end of its travel, and in a non-volatile state when it is positioned either upright or inverted and descends to the end of its travel. Therefore, it is possible to easily switch between the volatile and non-volatile states.

[0101] Furthermore, the vertical movement of the inner container 10 is restricted by the first protrusion 14 protruding from the outer surface of the inner container 10 abutting against the second protrusion 24 protruding from the inner surface of the outer container 20. Therefore, the inner opening 10a can be easily positioned relative to the outer opening 20a and configured in either a volatile or non-volatile state.

[0102] Furthermore, the inner container 10 can be detached from the outer container 20, allowing for the replacement of the drug vapor 5. It should be noted that, for example, the insertion hole 20c can be blocked to prevent the inner container 10 from being detached from the outer container 20. Alternatively, the inner container 10 can be reused repeatedly by unfastening the inner container 10 and replacing the drug vapor 5.

[0103] Industrial applicability

[0104] According to the present invention, a drug volatilization device is available for volatilizing volatile agents such as insecticides, repellents, fungicides, antibacterial agents, fragrances, deodorizers, and synergists.

[0105] Explanation of reference numerals in the attached figures

[0106] 1. Drug volatilization device

[0107] 5. Pharmaceutical volatiles

[0108] 6 Storage Containers

[0109] 10 Inner Container

[0110] 10a Inner opening

[0111] 10b, 20b lattice

[0112] 11 Surface components

[0113] 12 Backside components

[0114] 13. Widening section

[0115] 14 First protrusion

[0116] 15 raised holes

[0117] 15a, 15b locking claws

[0118] 16 protrusions

[0119] 16. The part that was stuck together

[0120] 17 Storage Department

[0121] 18 Flanges

[0122] 19. Elevated section

[0123] 20 Outer Container

[0124] 20a Outer opening

[0125] 20c through hole

[0126] 20d upper surface opening

[0127] 21, 21' Surface members

[0128] 22' Backside Members

[0129] 23 Flange

[0130] 23a convex part

[0131] 24 Second protrusion

[0132] 25a, 25a', 25b, 25b' Engaging claws

[0133] 26a, 26a', 26b, 26b' Ribs

[0134] Steps 28a, 29a, 28b, 29b

[0135] 30a and 30b are stuck together.

[0136] 31a, 31a', 31b, 31b' Opposite walls

[0137] 32a Protrusion

[0138] 32a, 32b protrusions

[0139] 32b Protrusion

[0140] Steps 33a and 33b

[0141] 35 Limiting components

[0142] Arrow A.

Claims

1. A pharmaceutical vaporization device comprising a container for retaining a volatile pharmaceutical agent as a vaporizable pharmaceutical vapor and a receiving container having an outer container disposed outside an inner container for receiving the vaporizable pharmaceutical vapor. The pharmaceutical vaporization device is characterized in that... When the storage container is switched to an upright position and then to an inverted position with the top and bottom reversed relative to the upright position, the inner container descends under its own weight. In one of the upright postures and the inverted postures, the outer opening of the outer container's circumferential opening overlaps with the inner opening of the inner container's circumferential opening. In the other of the upright postures and the inverted postures, the inner opening is offset relative to the outer opening in the vertical direction, and the outer opening is blocked by the surrounding area of ​​the inner opening.

2. The drug vaporization device according to claim 3, characterized in that, The inner container has a laterally wider portion, which is wider than the lateral width on the first protrusion, at one end in the vertical direction and is inserted into the through hole from the opposite side of the laterally wider portion. When inserted in the opposite direction, the laterally wider portion abuts against the second protrusion and obstructs the movement of the inner container.

3. A pharmaceutical vaporization device comprising a container for retaining a volatile pharmaceutical agent as a vaporizable pharmaceutical vapor and a receiving container having an outer container disposed outside an inner container for receiving the vaporizable pharmaceutical vapor. The pharmaceutical vaporization device is characterized in that... The inner container, made of a sheet-formed synthetic resin, is configured to move vertically relative to the outer member, made of an injection-molded synthetic resin. By moving the inner container up and down, it is possible to switch between a volatile state in which the outer opening of the outer container overlaps with the inner opening of the inner container, and a non-volatile state in which the inner opening is offset from the outer opening in the vertical direction and the outer opening is blocked by the inner opening.

4. The drug vaporization device according to claim 3, characterized in that, The volatile state occurs when the outer container is configured in either an upright position or an inverted position with the top and bottom reversed relative to the upright position, and the inner container descends to the end of its stroke. The non-volatile state occurs when the outer container is configured in either the upright position or the inverted position, and the inner container descends to the end of its stroke.

5. The pharmaceutical vaporization device according to claim 1 or 3, characterized in that, A first protrusion protruding from the outer surface of the inner container abuts against a second protrusion protruding from the inner surface of the outer container, thereby restricting the vertical movement of the inner container.

6. The pharmaceutical vaporization device according to claim 5, characterized in that, The outer container has an insertion hole on one end face in the vertical direction through which the inner container is inserted. The inner container is detachable from the outer container. When the inner container is inserted through the insertion hole, the first protrusion slides and passes over the second protrusion.

7. The pharmaceutical vaporization device according to claim 1 or 3, characterized in that, The inner container can be loaded and unloaded relative to the outer container.

8. The pharmaceutical vaporization device according to claim 1 or 3, characterized in that, The outer container has a front side member and a back side member that engage with each other. A locking claw is provided on one of the front side member and the back side member, and a locked portion engaged by the locking claw and a counter wall opposite the locked portion are provided on the other of the front side member and the back side member. The opposing wall has a protrusion facing the engaging claw inserted between the engaging portion and the opposing wall, and is positioned forward of the engaging portion in the insertion direction.

9. The pharmaceutical vaporization device according to claim 1 or 3, characterized in that, The inner container and the outer container have different exterior colors.

Images